Episode Summary: Your Anxiety Toolkit – “OCD Treatment in 2025: Updates in Research, Treatment & the Future”

Host: Kimberley Quinlan, LMFT
Guest: Dr. Jon Abramowitz, University of North Carolina Professor & OCD Researcher
Date: May 5, 2025
Episode Number: 432

Episode Overview

In this feature episode, host Kimberley Quinlan interviews Dr. Jon Abramowitz, a foremost OCD research and clinical expert, about the evolving landscape of OCD treatment in 2025. The conversation delves deeply into current "gold standard" therapies, gaps in research, misconceptions in clinical practice and among sufferers, the challenges of interpreting research in the age of social media and AI, and an optimistic vision for the future of personalized and inclusive OCD care.

Key Discussion Points & Insights

1. Current State of OCD Treatment in 2025 ([01:49])

• Progress Made:
  • ERP (Exposure and Response Prevention) is universally embraced as the “gold standard” for OCD.
  • Growing awareness and increasing numbers of clinicians trained in ERP.
  • More accessibility to resources and global conferences (e.g., IOCDF).
  • Expansion of online tools and support.
• Persistent Challenges:
  • High rates of misdiagnosis—even by professionals.
  • Some therapists still hesitant to use ERP, especially for taboo or existential themes.
  • Research predominantly includes less diverse populations; diversity in study participants is still lacking.

Quote:

“ERP is more than ever recognized as the gold standard treatment that we have. ... But there are still some gaps. Many people are still misdiagnosed—even by mental health professionals.”
—Dr. Jon Abramowitz (02:00)

2. Understanding & Interpreting OCD Research ([05:15])

• Dr. Abramowitz emphasizes how difficult it is for the average person (and sometimes clinicians) to recognize quality research.
• Key ways to spot higher quality studies:
  • Large and diverse participant groups.
  • Use of randomized controlled trials (RCTs) versus small, uncontrolled studies.
  • Independence of research teams (not just the creators of new treatments).
• The risk of misinformation on social media and with AI tools (e.g., ChatGPT hallucinating citations).

Memorable Moment:
Kimberley shares how ChatGPT fabricated a scholarly article, underscoring the need for skepticism and careful verification of sources ([07:47]).

Quote:

"A poorly done study can look just as factual as a really rigorously done study, depending on where it gets posted or who posts it."
—Dr. Jon Abramowitz (05:20)

3. Meta-Analyses and What They Reveal About OCD Treatments ([09:34])

• Meta-analyses aggregate results across multiple studies to clarify treatment efficacy.
• The evidence overwhelmingly supports ERP as a robust and effective treatment, both immediately post-treatment and in follow-ups.
• ERP improves and maintains gains for many, though not for all—OCD is rarely ever “cured.”

Quote:

“Time after time they show the same results that we know that ERP works and it works well... and, once people stop doing ERP... the gains tend to be kept.”
—Dr. Jon Abramowitz (09:34)

4. Supplemental & Alternative Treatments: ACT, ICBT & More ([12:50])

• ACT (Acceptance and Commitment Therapy) paired with ERP may benefit some, but “averages” in studies suggest little additive value; individual patient fit is crucial.
• Inference-based CBT (ICBT) is an emerging modality—current research is mostly by its creators, so independent validation is still needed.
• DBT (Dialectical Behavior Therapy) is generally not warranted for OCD specifically, unless comorbid emotional dysregulation is severe.

Quote:

"With ACT and exposure and response prevention together... for some people, maybe we can get more out of using ACT. Not for everyone."
—Dr. Jon Abramowitz (13:30)

5. Limitations in Biological Treatments & Commercialization ([14:54])

• Despite decades of brain imaging/genetics research, no significant advances in biological treatments since SSRIs (Prozac, 1988).
• Commercial “quick fixes”—like ketamine, deep brain stimulation—are experimental, not first-line, and often aggressively marketed.

Quote:

“All of this money to help us understand [OCD biologically] has not helped us really one bit when it comes to biological treatments.”
—Dr. Jon Abramowitz (15:53)

6. Common Misconceptions about OCD ([20:20])

• OCD is not just about hand-washing or neatness (“not just quirky or cute”).
• Harmful social perceptions linger—even among therapists.
• Some believe ERP is risky or unethical, particularly imaginal exposures; this is untrue, and evidence-based ERP requires compassion and collaboration.

Notable Moment:
Dr. Abramowitz recounts seeing a comedian make jokes about OCD in 2025, highlighting the need for greater public education ([20:49]).

7. Why ERP Sometimes “Fails”—and What that Really Means ([22:23])

• Bad ERP experiences often stem from poor therapist preparation: going too fast, lack of education, insufficient collaboration.
• Good ERP should involve psychoeducation, client buy-in, and a gradual, compassionate approach.
• Anecdotal refusal (“ERP didn’t work for me”) often reflects the therapy setup, not ERP itself.

Quote:

“People who are well trained… know that you need to explain the rationale for ERP and get the person’s buy-in and go gradually and do it with compassion.”
—Dr. Jon Abramowitz (23:31)

8. Interpreting Therapy Outcomes: Placebo & Nonspecific Effects ([32:06])

• Therapist-client relationship, hope, and expectations (non-specific effects) are major factors—present in all therapies.
• Research tries to control for these effects with placebos and active control conditions; this is easier in drug research than in psychotherapy.

Quote:

“There are also important non specific placebo effects. And that’s the case with any psychotherapy.”
—Dr. Jon Abramowitz (36:05)

9. Do-It-Yourself ERP: Best Practices for Self-Help ([39:18])

• Social support is crucial—having an accountability partner, “cheerleader,” or coach can mimic nonspecific benefits of therapy.
• Biggest challenge is doing ERP correctly; self-help can inadvertently reinforce avoidance.

Quote:

“It’s really easy to do ERP incorrectly… having someone there to help you get through that and give you encouragement… that’s what the non specifics are all about.”
—Dr. Jon Abramowitz (39:47)

10. The Future of OCD Treatment (2025 & Beyond) ([40:53])

• Need for personalized treatments—no “one size fits all”; consideration of individual client needs, backgrounds, and comorbidities.
• Early detection, especially in kids/teens and perinatal OCD (including partners).
• More research needed in:
  • Lesser-known OCD types (e.g., existential obsessions)
  • Digital assessment and treatment tools
  • Family-based interventions (without excessive accommodation)
  • Diversity and inclusivity in research and care

Quote:

“We need to personalize our treatments too… OCD is not one size fits all.”
—Dr. Jon Abramowitz (41:12)

Notable Quotes & Memorable Moments

1. “ERP is more than ever recognized as the gold standard… but there are still some gaps.”
   —Dr. Jon Abramowitz (02:00)

2. “A poorly done study can look just as factual as a really rigorously done study, depending on, you know, where it gets posted or who posts it or what they say about it.”
   —Dr. Jon Abramowitz (05:20)

3. “We want lots of people in a study before we can say that it works.”
   —Dr. Jon Abramowitz (07:02)

4. “Since 1988, when Prozac came out, we're still using the same biological treatments… all of this money to help us understand has not helped us really one bit when it comes to biological treatments.”
   —Dr. Jon Abramowitz (15:53)

5. “There are also important non-specific placebo effects. And that’s the case with any psychotherapy.”
   —Dr. Jon Abramowitz (36:05)

6. “People with OCD are not widgets to be stamped out.”
   —Dr. Jon Abramowitz (41:47)

7. “I think there’s hope for the future. ... This is a passionate community.”
   —Dr. Jon Abramowitz (49:22)

Timestamps for Important Segments

• [01:49] - The current state of OCD treatment (progress & remaining gaps)
• [05:15] - How to spot quality scientific research
• [09:34] - What meta-analyses say about ERP and OCD treatment outcomes
• [14:54] - Limits of biological treatments and commercial “quick fixes”
• [16:37] - Summing up: what works, and how treatments are being optimized
• [20:20] - Persistent misconceptions about OCD & ERP (public and clinical)
• [22:23] - Why some ERP experiences fail, and what good ERP should involve
• [32:06] - Parsing anecdote from science, and understanding therapy outcome research
• [39:18] - Tips for those self-administering ERP
• [40:53] - Research priorities and hopes for more individualized, inclusive care

Resources and Where to Learn More

• Dr. Jon Abramowitz:
  • jabramowitz.com: Free resources and workbooks for clients, families, and clinicians
  • Latest Book: Living Well with OCD (with strategies for real-world management and support)
  • University of North Carolina faculty page (for current research and publications)
• Research Access:
  • Google Scholar: For research articles and meta-analyses on OCD treatment. Email authors for full texts if needed.
• International OCD Foundation:
  • IOCDF.org: For conferences, training, and global community resources.

Final Words

The conversation closes on a hopeful note:

"Every time someone shares their story of having OCD or working with someone… and I hear about how folks are, you know, approaching, leaning into their fear instead of running away from it. It just reinforces how much hope that we have where we can really help people to reclaim their lives."
—Dr. Jon Abramowitz (49:22)

For listeners:
This episode offers a mix of cutting-edge research insights, practical clinical considerations, and a compassionate, realistic look at the nuances of effective OCD treatment in 2025 and beyond. Whether you’re a sufferer, clinician, or simply keen to understand the OCD landscape, this wide-ranging and relatable dialogue will leave you better informed—and hopeful.